Drug Trial Radar · NCT04248465
An Efficacy and Safety Study of Ravulizumab in ALS Participants
Last checked: Nov 20, 2026Latest source record: Jan 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
382
Actual
Start
Mar 30, 2020
Primary completion
Oct 17, 2021
Study completion Oct 17, 2021
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.
Conditions
- Amyotrophic Lateral Sclerosis
- ALS
Interventions
PlaceboDrug
Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
RavulizumabBiological
Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total ScoreTime frame: Baseline, Week 50
Locations
95 sites in 17 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
Neuromuscular Research Center and Clinic
Phoenix, Arizona
HonorHealth Research Institute
Scottsdale, Arizona
Loma Linda University Medical Center
Loma Linda, California
University of Southern California
Los Angeles, California
University of California-Irvine
Orange, California
Stanford University Medical Center
Palo Alto, California
University of California San Diego Medical Center
San Diego, California
Norris MDA/ALS Center
San Francisco, California
University of California San Francisco Medical Center
San Francisco, California
University of Colorado Anschutz Medical Campus School of Medicine
Aurora, Colorado
University of Florida at Shands Jacksonville
Jacksonville, Florida
University of South Florida
Tampa, Florida
University of Chicago Medical Center
Chicago, Illinois
Indiana University Medical Center
Indianapolis, Indiana
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
Johns Hopkins University School Of Medicine
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Las Vegas Clinic
Las Vegas, Nevada
Beth Israel Medical Center - PRIME
New York, New York
Hospital for Special Surgery
New York, New York
Atrium Health Neuroscience Institute
Charlotte, North Carolina
The Cleveland Clinic Foundation
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Allegheny Neurological Associates
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Austin Neuromuscular Center
Austin, Texas
Houston Methodist Neurological Institute-Movement Disorders Clinic
Houston, Texas
Nerve & Muscle Center of Texas
Houston, Texas
University of Vermont Medical Center
Burlington, Vermont
Virginia Commonwealth University, Neurology Clinical and Translational Research Office
Richmond, Virginia
Sentara Neurology Specialists
Virginia Beach, Virginia
Swedish Neuroscience Institute
Seattle, Washington
Brain and Mind Centre
Camperdown, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Perron Institute for Neurological and Translational Science
Nedlands, Western Australia, Australia
UZ Leuven
Leuven, Belgium
Heritage Medical Research Centre (HMRC)
Edmonton, Alberta, Canada
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.